

UNLOCKING WHY NOW IS THE TIME FOR BIOPHARMA COMPANIES TO TRANSFORM

THESE ARE STILL EARLY DAYS FOR **CONNECTED HEALTH**

Maturity of the connected health enterprise is low

The majority of biopharma companies are still developing their connected health strategy

% of respondents who agree with the statements

We are testing or have approved connected health product(s) in market

16% 84%

We are still strategizing our approach to connected health

Source: Capgemini Research Institute, connected health survey, October–November 2021, N = 523 biopharma respondents.

For the purposes of this research, the definition of connected health covers a wide spectrum of digital health products and services, from digital wellness products such as consumer wearables to clinically validated solutions such as digital companions, digital therapeutics (DTx), and combination DTx, including Software-as-a-Medical Device (SaMD).

Roughly a quarter said their organization is mature in portfolio strategy, product design, and product development

% of respondents that define the maturity of their organization's connected health enterprise as mature or emerging

26%



Source: Capgemini Research Institute, connected health survey, October–November 2021, N = 523 biopharma respondents.

Digital, technology, and collaboration capabilities are under development



Most connected health use cases are planned for the next five years

With the exception of a mobile app and remote patient monitoring,

less than 20%

of biopharma executives said their company had developed a proof of concept for any use case the research explored



In the next 5 years:

are planning to initiate 54% are planning to init digital biomarker applications

51% are planning to initiate AI-enabled predictive diagnostics

CHALLENGES MUST BE OVERCOME FOR CONNECTED HEALTH TO FULFILL AMBITIONS

Security, technology, and regulatory are major roadblocks

of biopharma executives said that security vulnerabilities is the 58% of biopharma executives said that security vulner abilities is the top challenge their organizations' face and 120% said regulatory O approval

O out of companies do not have a structured process for measuring the success of connected health products

There is a critical technical skill gap

The skills in most plentiful supply are in softer managerial skills, such as communications and agile product management



Augmented/virtual reality, systems thinking and interoperability, engineering, and human-centered **design** are the technical skills with the greatest shortage

CONNECTED HEALTH IS SET TO REVOLUTIONIZE HEALTHCARE AND DRIVE BUSINESS VALUE

of biopharma executives agree that connected health will create new treatment pathways, and that it will make healthcare more personalized and integrated

The perceived market opportunity for connected health is extensive

84% of biopharma executives said that the opportunity for connected health exceeds that offered by their traditional drug businesses

% of respondents who agree with the statement:

"The market opportunity for connected health is bigger than our traditional drug business."

84%

97%









Source: Capgemini Research Institute, connected health survey, October–November 2021, N = 523 biopharma respondents; N = 281 biopharma respondents in the US; N = 182 biopharma respondents in Europe.

On average, connected health products are projected to represent 13% of total revenue in five years' time

Connected health product portfolios are expected to grow by 40% in the next five years

On average, **59%** of connected health portfolios will be products for the treatment of existing diseases within current therapeutic areas in five years' time

> The top two therapeutic areas for connected health in the next five years are **neuroscience** and rare diseases

HOW BIOPHARMA COMPANIES CAN CLOSE THE MATURITY **GAP AND SCALE THEIR CONNECTED HEALTH PORTFOLIOS**



Source: Capgemini Research Institute analysis.



Subscribe to the latest research from the Capgemini Research Institute by visiting https://www.capgemini.com/capgemini-research-institute-subscription/

This message contains information that may be privileged or confidential and is the property of the Capgemini Group. Copyright © 2022 Capgemini. All rights reserved.